Tags

Type your tag names separated by a space and hit enter

Influence of Vitreomacular Adhesion on Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration.
Ophthalmic Res 2017; 58(1):18-26OR

Abstract

PURPOSE

To investigate the effect of vitreomacular adhesion (VMA) on the outcome of antiangiogenic treatment for neovascular age-related macular degeneration (AMD).

METHODS

Ninety-nine eyes of 83 patients were used in our cohort study. We prospectively evaluated best corrected visual acuity (BCVA) and central retinal thickness (CRT) in patients with neovascular AMD at baseline and 1, 2, 3, 6, and 12 months after treatment with anti-vascular endothelial growth factor (anti-VEGF) agents. All patients were stratified by spectral domain optical coherence tomography into 2 groups (i.e., VMA[+] and VMA[-]) according to the presence or absence of VMA, and the response to treatment was evaluated.

RESULTS

Fifty-four eyes (54.5%) were included in the VMA(-) group and 45 eyes (45.5%) comprised the VMA(+) group. In paired comparisons of mean BCVA between baseline and each follow-up visit (1, 2, 3, 6, and 12 months), the VMA(-) group showed statistically significant improvement at 1, 2, and 3 months compared to baseline, and BCVA significantly improved only at 3 months in the VMA(+) group. For both groups, paired comparisons of CRT showed a statistically significant decrease when data obtained at 1, 2, 3, 6, and 12 months were compared to baseline values (p < 0.05).

CONCLUSIONS

Posterior VMA is associated with a worse short-term outcome in patients with neovascular AMD treated with anti-VEGF agents.

Authors+Show Affiliations

Department of Ophthalmology, Federal University of Minas Gerais, Belo Horizonte, Brazil.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28301850

Citation

Kanadani, Tereza Cristina Moreira, et al. "Influence of Vitreomacular Adhesion On Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration." Ophthalmic Research, vol. 58, no. 1, 2017, pp. 18-26.
Kanadani TCM, Dos Reis Veloso CE, Dorairaj S, et al. Influence of Vitreomacular Adhesion on Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration. Ophthalmic Res. 2017;58(1):18-26.
Kanadani, T. C. M., Dos Reis Veloso, C. E., Dorairaj, S., & Nehemy, M. B. (2017). Influence of Vitreomacular Adhesion on Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration. Ophthalmic Research, 58(1), pp. 18-26. doi:10.1159/000459626.
Kanadani TCM, et al. Influence of Vitreomacular Adhesion On Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration. Ophthalmic Res. 2017;58(1):18-26. PubMed PMID: 28301850.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Influence of Vitreomacular Adhesion on Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration. AU - Kanadani,Tereza Cristina Moreira, AU - Dos Reis Veloso,Carlos Eduardo, AU - Dorairaj,Syril, AU - Nehemy,Márcio Bittar, Y1 - 2017/03/17/ PY - 2016/08/24/received PY - 2017/02/05/accepted PY - 2017/3/17/pubmed PY - 2017/9/2/medline PY - 2017/3/17/entrez KW - Antiangiogenic treatment KW - Neovascular age-related macular degeneration KW - Vitreomacular adhesion SP - 18 EP - 26 JF - Ophthalmic research JO - Ophthalmic Res. VL - 58 IS - 1 N2 - PURPOSE: To investigate the effect of vitreomacular adhesion (VMA) on the outcome of antiangiogenic treatment for neovascular age-related macular degeneration (AMD). METHODS: Ninety-nine eyes of 83 patients were used in our cohort study. We prospectively evaluated best corrected visual acuity (BCVA) and central retinal thickness (CRT) in patients with neovascular AMD at baseline and 1, 2, 3, 6, and 12 months after treatment with anti-vascular endothelial growth factor (anti-VEGF) agents. All patients were stratified by spectral domain optical coherence tomography into 2 groups (i.e., VMA[+] and VMA[-]) according to the presence or absence of VMA, and the response to treatment was evaluated. RESULTS: Fifty-four eyes (54.5%) were included in the VMA(-) group and 45 eyes (45.5%) comprised the VMA(+) group. In paired comparisons of mean BCVA between baseline and each follow-up visit (1, 2, 3, 6, and 12 months), the VMA(-) group showed statistically significant improvement at 1, 2, and 3 months compared to baseline, and BCVA significantly improved only at 3 months in the VMA(+) group. For both groups, paired comparisons of CRT showed a statistically significant decrease when data obtained at 1, 2, 3, 6, and 12 months were compared to baseline values (p < 0.05). CONCLUSIONS: Posterior VMA is associated with a worse short-term outcome in patients with neovascular AMD treated with anti-VEGF agents. SN - 1423-0259 UR - https://www.unboundmedicine.com/medline/citation/28301850/Influence_of_Vitreomacular_Adhesion_on_Anti_Vascular_Endothelial_Growth_Factor_Treatment_for_Neovascular_Age_Related_Macular_Degeneration_ L2 - https://www.karger.com?DOI=10.1159/000459626 DB - PRIME DP - Unbound Medicine ER -